- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Roche's injectable PD-L1 inhibitor granted FDA approval for multiple cancer types | ||
| Mo | Eli Lilly announces FDA approval for Ebglyss in moderate-to-severe atopic dermatitis | ||
| Mo | Merck shares positive ten-year results for Keytruda in advanced melanoma | ||
| Fr | Sanofi, RadioMedix and Orano Med partner to develop rare cancer therapy in deal worth €320m | ||
| Fr | GSK's mRNA seasonal flu vaccine shows promise in younger and older adults | ||
| Fr | Common antidiabetic drug metformin found to slow growth of precancerous cells | ||
| Fr | The challenge of environmental management in the pharma industry | ||
| Fr | PM Society Digital Awards 2024 - winners announced | ||
| Do | Johnson & Johnson's IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis | ||
| Do | Sanofi/Regeneron's Dupixent approved by MHRA to treat uncontrolled COPD | ||
| Do | Pfizer's Elrexfio accepted by SMC to treat relapsed and refractory multiple myeloma | ||
| Do | Climate of Health: the prescription for survival | ||
| Mi | Sanofi/Regeneron announce positive late-stage results for Dupixent in chronic spontaneous urticaria | ||
| Mi | Gilead and AI-focused Genesis partner to develop small molecule therapies | ||
| Mi | Merck and Daiichi Sankyo's ADC candidate ifinatamab deruxtecan shows promise in SCLC | ||
| 10.09. | Eli Lilly and Genetic Leap partner to develop RNA-targeted therapies in deal worth $409m | ||
| 10.09. | Regeneron's Libtayo shows durable survival benefits in phase 3 lung cancer study | ||
| 10.09. | GSK shares positive phase 3 results for long-acting biologic in severe asthma | ||
| 09.09. | FDA grants full approval to Travere's Filspari for rare kidney disease IgA nephropathy | ||
| 09.09. | Eli Lilly's once-weekly insulin candidate shows promise in late-stage diabetes trials | ||
| 09.09. | J&J presents positive late-stage results for Rybrevant/Lazcluze combination in NSCLC | ||
| 06.09. | Eli Lilly and HAYA Therapeutics enter metabolic condition partnership worth $1bn | ||
| 06.09. | GSK announces positive late-stage results for IL-5 inhibitor Nucala in COPD | ||
| 06.09. | Pfizer/Valneva share promising results for Lyme disease vaccine candidate | ||
| 06.09. | Worldwide Clinical Trials appoints Alessandra Vignola as president of cardiovascular and metabolic |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
